The next step for health care professionals is to teach patients how to act on the data collected by intermittently scanned glucose sensing technologies, according to Viral Shah, MD, an endocrinologist and scientist.
When it comes to diabetes technologies, the combination of the correct use, by the correct patients, in the correct manner is what leads to good outcomes, said Viral Shah, MD, endocrinologist and associate professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, Adult Clinic School of Medicine at the University of Colorado Anschutz campus.
Transcript
What are the more common reasons why patients might fail to achieve optimal glycemic control even while using these technologies?
This is another excellent question. I give this analogy like, OK, I have an iPhone, an iWatch, but I don't use every single function in that. That means I'm not optimally using that. Similarly, in the diabetes technology space, if you do not use that optimally, you're not going to achieve the optimal outcomes. A couple of examples for that is many patients with type 1 or type 2 diabetes who are on intermittently scanned glucose sensing technologies, where you have to scan it, if you don't scan it, you don't see the number. And if you don't see the number, you're not going to make any action.
Ultimately, it's not about the use of technology, but the right use of a technology in the right patient, in the right manner, that leads to a good outcome. So I think all the health care professionals and everybody needs to not just the promote the technology, but also advise the patient on how to use it, how to review the data meaningfully, how to act based on the data. And if you don't act, you're not going to achieve the good results. So I think with the promotion of diabetes technology, the next step for us is now teaching our patients how to act on those data, and I think that will help to optimize the outcome.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
2 Commerce Drive
Cranbury, NJ 08512